Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.44 |
| ▸ | JAK3 | P52333 | 16/20 | 0.44 |
| ▸ | JAK2 | O60674 | 13/20 | 0.44 |
| ▸ | JAK1 | P23458 | 13/20 | 0.44 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22055075 | 1.00 | TYK2 (0.44) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22054611 | 0.92 | TYK2 (0.46) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22054610 | 0.92 | TYK2 (0.46) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL23878952 | 0.89 | TYK2 (0.49) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL30146792 | 0.89 | TYK2 (0.49) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22054218 | 0.89 | TYK2 (0.49) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL23879060 | 0.88 | JAK2 (0.57) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22055383 | 0.88 | JAK2 (0.57) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22055081 | 0.88 | PLK4 (0.45) | TYK2JAK3JAK2JAK1PLK4 | |
| SCHEMBL22055080 | 0.88 | PLK4 (0.45) | TYK2JAK3JAK2JAK1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667228-A | Salt and crystal form of heteroaromatic derivative and preparation method of salt and crystal form | 上海翰森生物医药科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-116003441-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115925705-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-115667228-A | Salt and crystal form of heteroaromatic derivative and preparation method of salt and crystal form | 上海翰森生物医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-111511738-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2021238908-A1 | SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | TYK2 105/4885JAK3 88/4885JAK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.